Taysha Gene Therapies, Inc. (TSHA)
NASDAQ:TSHA
Want to see TSHA full AI Analyst Report?
Earnings Data
Report Date
Aug 17, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.12Last Year’s EPS
-0.09Same Quarter Last Year
Strong Buy
Based on 9 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed strong clinical, preclinical and regulatory momentum for TSHA-102 — including FDA alignment on a potential expedited pathway, robust Part A efficacy signals (high response rates, multiple developmental milestones and functional gains), initiation of BLA-enabling PPQ, and a solid cash position with runway into 2028. These positives are tempered by materially higher R&D and G&A spending that drove a near-doubling of net loss year-over-year, ongoing uncertainty around whether the FDA will accept a 6-month interim for full approval versus requiring 12-month data, and the need to complete PPQ and validate manufacturing redundancy. Overall, the operational and scientific progress appears to outweigh the financial and timing risks at this stage.Company Guidance
Regulatory Progress and FDA Alignment
Held a Breakthrough Therapy Type B multidisciplinary meeting with the FDA that reaffirmed alignment on the planned pathway toward a BLA for TSHA-102, including the option to submit based on a 6-month interim analysis; held a Type C meeting where the FDA endorsed the proposed PPQ campaign strategy; initiated the BLA-enabling PPQ campaign using the commercial manufacturing process in April 2026 and expect to complete PPQ execution by Q4 2026.
Clinical Efficacy Signals and Safety Profile
Advanced dosing in the REVEAL pivotal and ASPIRE trials and remain on track to complete dosing in Q2 2026; as of the May 2026 data cutoff, both high and low doses were generally well tolerated with no treatment-related serious adverse events (SAEs) or dose-limiting toxicities (DLTs) observed across REVEAL Phase I/II, pivotal and ASPIRE trials; Part A prior results: 83% response rate at 6 months (high-dose cohort) and 100% response rate at 9 months among the 6 high-dose patients; Part A reported 22 developmental milestones across 10 patients and 165 additional functional skills/improvements (approximately 19 functional gains per patient); expecting longer-term (≥12 months) follow-up data for all 12 Part A patients later this quarter.
Preclinical Validation of Delivery Route and Construct
Peer-reviewed NHP data published showing lumbar intrathecal delivery and intra-cisterna magna administration produced comparable, consistent and widespread AAV9 distribution throughout brain and spinal cord; ASGCT 2026 preclinical data show self-complementary AAV9 yields ~30-fold higher transduction/protein expression versus single-stranded AAV9 in neuronal mouse models; mini MECP2 used in TSHA-102 demonstrated functional comparability to full-length MECP2 across molecular/biochemical assays — supporting the minimally invasive intrathecal approach and construct design.
Commercial Readiness and Market Demand
Built out commercial leadership with senior hires experienced in gene-therapy launch, payer and health system engagement; market research indicates strong clinician and caregiver preference for minimally invasive intrathecal delivery (scalability and familiarity) and high demand across age ranges; company plans to share additional commercial strategy details in H2 2026.
Solid Cash Position and Runway
Cash and cash equivalents of $276.6 million as of March 31, 2026; management expects current cash resources are sufficient to fund planned operating expenses into 2028.
TSHA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
TSHA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 06, 2026 | $6.94 | $6.98 | +0.58% |
Mar 19, 2026 | $4.45 | $4.56 | +2.47% |
Nov 04, 2025 | $4.46 | $4.27 | -4.26% |
Aug 12, 2025 | $2.76 | $2.91 | +5.43% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Taysha Gene Therapies, Inc. (TSHA) report earnings?
Taysha Gene Therapies, Inc. (TSHA) is schdueled to report earning on Aug 17, 2026, Before Open (Confirmed).
What is Taysha Gene Therapies, Inc. (TSHA) earnings time?
Taysha Gene Therapies, Inc. (TSHA) earnings time is at Aug 17, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is TSHA EPS forecast?
TSHA EPS forecast for the fiscal quarter 2026 (Q2) is -0.12.